The Effect of Prostaglandin Analogues on Central Corneal Thickness of Patients with Glaucoma or Ocular Hypertension: a systematic review

被引:0
|
作者
Lu, Ye [1 ]
Zhong, Enyu [1 ]
Wu, Jing [2 ,3 ]
Cao, Yang [1 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Ophthalmol, 1277 Jiefang Ave, Wuhan 430022, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Key Lab Environm &Hlth,Minist Educ, Wuhan, Peoples R China
[3] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan, Peoples R China
关键词
OPEN-ANGLE GLAUCOMA; INTRAOCULAR-PRESSURE; MATRIX METALLOPROTEINASES; BIOMECHANICAL PROPERTIES; TRAVOPROST; 0.004-PERCENT; APPLANATION TONOMETRY; TISSUE INHIBITORS; PRESERVATIVE-FREE; RISK-FACTORS; LATANOPROST;
D O I
10.1159/000528461
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: A meta-analysis of observational studies was conducted to evaluate the effect of prostaglandin analogues (PGAs) on central cornea thickness (CCT) of patients with glaucoma and ocular hypertension (OHT). Methods: A literature search was performed through Pubmed, Embase, Cochrane Library, the System for Information on Grey Literature in Europe (Open Grey), ClinicalTrials.gov, and reference lists of retrieved studies. Observational studies were included in our meta-analysis. The final CCT of patients and 95% confidence interval (CI) from each study were extracted. Study quality was assessed using The Newcastle-Ottawa Scale (NOS) and the Agency for Healthcare Research and Quality (AHRQ). A fixed-effects model was used to calculate the weighted mean difference (WMD) and 95% confidence interval (CI). Subgroup analyses based on several stratified factors were also performed. Results: Five cohort studies, five case-control, three cross-sectional studies involving 2722 subjects were included. The pooled effect of all thirteen studies showed PGAs can reduce CCT of patients with glaucoma or OHT slightly but significantly (WMD, -9.37; 95% CI [-12.18, -6.57], P =0.00; I2 = 45.5%). And significant results were observed in all specific study design ( WMD, -5.17; 95% CI [-9.52, -0.82] for cohort study; WMD, -15.31; 95% CI [-22.66, -7.97] for case-control study; WMD, -8.65; 95% CI [-17.30, -0.01] for cross-sectional study). Also, subgroup analysis of exposure time showed the effect of PGAs was more obvious in the first two years (WMD, -5.81; 95% CI [-9.49, -2.14] for 1 year; WMD, -13.02; 95% CI [-20.03, -6.01] for 2 years). Conclusions: The pooled effects from current literature suggest that PGAs use could reduce CCT of patients with glaucoma or OHT slightly but significantly, and this effect is more pronounced in the first two years. This reminds us that we need to pay attention to the changes in CCT during the first two years of PGA use in case we misestimate intraocular pressure (IOP) and the efficacy of the PGA.
引用
收藏
页码:431 / 444
页数:14
相关论文
共 50 条
  • [31] Central corneal thickness and intraocular pressure in ocular hypertension
    Gutierrez, C
    Casaponsa, JRV
    Munoz, F
    Rebolleda, G
    [J]. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2001, 239 (06) : 463 - 463
  • [32] Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or β-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis
    Liu, Yuanzhi
    Zhao, Junyi
    Zhong, Xiaoyan
    Wei, Qiming
    Huang, Yilan
    [J]. FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [33] Increased corneal thickness in patients with ocular hypertension
    Herman, DC
    Hodge, DO
    Bourne, WM
    [J]. ARCHIVES OF OPHTHALMOLOGY, 2001, 119 (03) : 334 - 336
  • [34] Central corneal thickness in patients with and without glaucoma
    Shafranov, G
    Soltau, JB
    Harmon, H
    Shields, MB
    Zimmerman, TJ
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2000, 41 (04) : S515 - S515
  • [35] Central corneal thickness of Korean patients with glaucoma
    Lee, Eun Suk
    Kim, Chan Yun
    Ha, Seung Joo
    Seong, Gong Je
    Hong, Youno Jae
    [J]. OPHTHALMOLOGY, 2007, 114 (05) : 927 - 930
  • [36] Comparative results of central corneal thickness measurements in primary open-angle glaucoma, pseudoexfoliation glaucoma, and ocular hypertension
    Gorezis, Spiridon
    Christos, Gartzos
    Stefaniotou, Maria
    Moustaklis, Kostantinos
    Skyrlas, Aggelos
    Kitsos, Georgios
    [J]. OPHTHALMIC SURGERY LASERS & IMAGING, 2008, 39 (01) : 17 - 21
  • [37] Decreased keratocyte density and central corneal thickness in primary open-angle glaucoma patients undergoing treatment with topical prostaglandin analogues
    Kocabeyoglu, Sibel
    Mocan, Mehmet C.
    Irkec, Murat
    [J]. INDIAN JOURNAL OF OPHTHALMOLOGY, 2015, 63 (01) : 15 - 19
  • [38] Central corneal thickness and corneal diameter in patients with childhood glaucoma
    Tania Tai, Tak Yee
    Mills, Monte D.
    Beck, Allen D.
    Joos, Karen M.
    Ying, Gui-shuang
    Liu, Chengcheng
    Piltz-Seymour, Jody R.
    [J]. JOURNAL OF GLAUCOMA, 2006, 15 (06) : 524 - 528
  • [39] Ocular Surface Tolerability of Prostaglandin Analogs in Patients with Glaucoma or Ocular Hypertension
    Whitson, Jess T.
    Trattler, William B.
    Matossian, Cynthia
    Williams, Julia
    Hollander, David A.
    [J]. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2010, 26 (03) : 287 - 292
  • [40] Central Corneal Thickness in the Ocular Hypertension Treatment Study (OHTS)
    Brandt, James D.
    Beiser, Jlia A.
    Kass, Michael A.
    Gordon, Mae O.
    [J]. OPHTHALMOLOGY, 2020, 127 (04) : S72 - S81